Floatz Rating
C39/100
Confidence
Indicative
Sponsor
National Cancer Institute (NCI)
Modality
UNKNOWN
Development Phase
Phase 1
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
28Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT02390752CT.gov Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ... | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Sarcoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Turalio (this asset) | National Cancer Institute (NCI) | P1 | C · 39 |
| Etoposide | National Cancer Institute (NCI) | P2 | BB |
| Cyclophosphamide | Essen Biotech | P2 | BB |
| Isocyclophosphamide | City of Hope Medical Center | P3 | BB |
| Carboplatin | OHSU Knight Cancer Institute | P2 | BB |
| Adriamycin | City of Hope Medical Center | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | Roswell Park Cancer Institute | P2 | BB |
| Nivestim | Masonic Cancer Center, University of Minnesota | P3 | BB |
| Sodium Thiosulfate | Mayo Clinic | P3 | BB |
+42 more in the Sarcoma cohort
Other indications for Turalio
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Acute Promyelocytic Leukemia | — | P1 | CC · 43 |
| Precursor Lymphoblastic Lymphoma/Leukemia | — | P1 | CC · 41 |
| Plexiform Neurofibroma | — | P1 | NR |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Turalio in Sarcoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/turalio-sarcoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →